IMA’s open letter to Prime Minister Narendra Modi

IMT News Desk
IMT News Desk
· 3 min read
stock NEET PG Results

In the recent “Bharat Ki Baat Sabke Saath” event, organised in London’s Westminster, Prime Minister Narendra Modi, cited examples of various international conferences allegedly funded by pharma companies, where doctors regularly participate.

He had said that to end the nexus between doctors and pharmaceutical companies, which results in the sale of expensive medicines the Centre has launched generic stores in India.

“Doctors visit Singapore, Dubai to attend conferences; they don’t go there because someone is sick. The pharma companies invite them for that. To finally break the resultant sale of expensive medicines the government has launched generic stores where medicines of similar quality are sold at cheaper prices,” the Prime Minister had said.

Many doctors have taken exception to the PM’s remarks. Expressing their concern through social media and open letters doctors have expressed hurt and humiliation brought on them by the remarks.

Below is the letter written by Dr Ravi Wankhedkar, National President IMA and Dr R N Tandon, Hony Secretary General IMA.

 

Beloved Prime Minister Shri Narendra Modiji

                                The patriarch of the family always speaks about his sons and daughters with pride especially with the strangers. This is our culture. Indian doctors have brought international acclaim and repute due to their world class proficiency and skill. Engaging in small talk  and  maligning the entire medical fraternity in India with broad brush  on foreign soil was certainly not expected out of the Prime Minister of the country.

The Health system of the country from where you commented on Indian doctors would collapse without Indian doctors. IMA expresses its displeasure on your unfortunate remarks.

We presume this is in no way connected with our resistance to the pro rich NMC Bill 2017. Doctors of this country are being suppressed and exploited by every means possible.  The onus of the mess in Health care squarely falls on the successive  Governments including yours.

·         IMA has declared its support for use of generic drugs. The only hitch is the issue of quality assurance. The current level of quality testing by the Government is less than 1% of the total drugs manufactured. In such a state of affairs how can doctors betray the confidence of the patients and support the populistic posturing of  the Government ?

·         IMA has supported and espoused the  Jan Oushadhi Scheme of 2008 . IMA hqs itself has an outlet of Jan Oushadhi drugs. We assure you Mr Prime Minister, the day you are able to assure the  quality of all the drugs manufactured in India, you will not find the doctors of this country wanting.

·         India has a robust price control policy for drugs. This being so why does  the Government allow huge profit margin in the Pharmaceutical industry?

·         Why is a pharma company allowed to price the  same drug categorised under different names with different profit margins?

·         Doctors of this country are in no way in control of  the price  of drugs or stents.

                                   We wish to point out that your unfortunate remarks have brought disrepute  to Indian doctors  and India. To that extent the goodwill and trust invested in you by Indian doctors stands  diminished.

 

 

 

Read Next

Zydus Wellness net sales up by 62.1% for Q4 & 46.4% for FY 26  
News
May 19, 2026

Zydus Wellness net sales up by 62.1% for Q4 & 46.4% for FY 26  

Zydus Wellness Limited reported a consolidated growth of 62.1% in Net Sales, which stood at Rs. 14,761 million as compared to Rs. 9,106 million in the corresponding period of the previous year. The Company reported annual Net Sales of Rs. 39,400 million, with a y-o-y growth of 46.4% in FY 26. EBITDA for the period […]
Article by: IMT News Desk
Strides Pharma delivers strong FY26 performance with 50% PAT growth, ex‑US markets up 21%
News
May 19, 2026

Strides Pharma delivers strong FY26 performance with 50% PAT growth, ex‑US markets up 21%

Strides Pharma Science Ltd. reported a robust FY26 performance, with consolidated EBITDA rising to ₹9,253 crore and operational profit after tax (PAT) at ₹5,181 crore, up 50.3% year‑on‑year. The company’s ex‑US markets outpaced the rest of the business, posting 21% YoY revenue growth, while disciplined execution expanded full‑year EBITDA margin to 19%, up 140 basis points from FY25. […]
Article by: IMT News Desk
Annora Pharma Expands Collaboration with AI-Native Traceability Platform AltiusHub to Strengthen Global Drug Traceability
News
May 18, 2026

Annora Pharma Expands Collaboration with AI-Native Traceability Platform AltiusHub to Strengthen Global Drug Traceability

Annora Pharma, the formulations subsidiary of Hetero Group, has expanded its collaboration with AltiusHub. The company is deploying AltiusHub’s AI-native serialization, track & trace and regulatory compliance platform across its export operations. The deployment is designed to improve serialization efficiency by up to 45%. It will also strengthen operational visibility across Annora Pharma’s global supply […]
Article by: IMT News Desk
WFNS Innovation & Technology Committee Announces Partnership with Time Medical International Ventures (India) Pvt Ltd for First-in-Class Medical Technology Innovation
News
May 18, 2026

WFNS Innovation & Technology Committee Announces Partnership with Time Medical International Ventures (India) Pvt Ltd for First-in-Class Medical Technology Innovation

The World Federation of Neurosurgical Societies (WFNS) Innovation & Technology Committee has announced collaboration with Time Medical International Ventures (India) Pvt. Ltd (Time Medical India)., a wholly owned subsidiary of Fischer Medical Ventures Limited, marking a significant milestone in advancing innovation in global neurosurgical care. This marks the first time the Committee has formally partnered […]
Article by: IMT News Desk